Canadian pharma company acquires developer of skin-penetrating technologies

Markham, ON – Pharmaceutical company Nuvo Research says it has acquired Fqubed, a San Diego, CA-based company that, in partnership with the University of California, Santa Barbara, has developed a proprietary technology to identify innovative formulations that can efficiently deliver active therapeutics through the skin.

“This acquisition is in line with Nuvo’s strategic vision of becoming a leading transdermal drug delivery company,” says Dan Chicoine, Nuvo’s chairman. “With the addition of Fqubed’s proprietary technology and in-house laboratory, we have significantly increased our capability to expand our portfolio of high performance skin penetrants which we will use to develop a broad pipeline of transdermally delivered therapeutics.”